ClinicalTrials.gg
RecruitingNCT06900153PARENT-HCSUpdated Nov 18, 2026

Parenting and CAH - 21-hydroxylase Deficiency

An observational study in CAH - 21-Hydroxylase Deficiency, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 7 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 18, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies in Adrenal Hyperplasia, Congenital with a site in France — 6 open to participants now, 8 under way, 4 of them phase 3. Adrenal Hyperplasia, Congenital · France.

Planned enrollment
3rd of 10
200 · median 94
Started
2026
with 3 others
Observational
10 of 21
3 open now
Registered
17th of 21
by date
Lead sponsor
6 of 21
Assistance Publique - Hôpitaux de Paris

Among the 21 studies in Adrenal Hyperplasia, Congenital with a site in France, this one is the 3rd largest by planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2026, is one of 10 observational ones, and was the 17th registered.

Adrenal Hyperplasia, Congenital

102 studies on the registry are indexed under Adrenal Hyperplasia, Congenital; 29 are open to participants now.

Browse Adrenal Hyperplasia, Congenital studies →

Open to participants now

6 of the 21 studies in Adrenal Hyperplasia, Congenital with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 20 Adrenal Hyperplasia, Congenital studies recruiting now, 10 (50%) set no upper age limit and 9 (45%) stop at 75 or younger; 7 take children under 18; none take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Adrenal Hyperplasia, Congenital with a site in France, or all of them as a file.
02

Study summary

Congenital adrenal hyperplasia (CAH) is a genetic disease with autosomal recessive transmission, which is defined by a deficiency of one of the steroidogenesis enzymes. 21-hydroxylase deficiency (21OHD), related to mutations of the CYP21A2 gene, is involved in 90 to 95% of CAH cases. Depending on the severity of the mutations of this gene, there are severe forms known as "classic" (FC), with neonatal onset, and moderate forms known as "non-classic" (FNC), with onset later in childhood or after puberty. The classic form includes the salt-wasting form and the pure virilizing form, depending on the degree of aldosterone deficiency. The sexuality and fertility of women with classic 21OHD deficiency are impaired by several factors such as disruption of the gonadotropic axis due to overproduction of androgens and progesterone by the adrenal glands, and mechanical and psychological factors related to genital surgery. The fertility of these women improves over time, largely due to earlier treatment of CAH, improved therapeutic compliance and surgical advances in genital reconstruction leading to an increase in the percentage of patients who are sexually active. However, there is little data available, and even less on the course of pregnancy, its complications and its outcomes.

03

Conditions studied

  • CAH - 21-Hydroxylase Deficiency

Keywords

  • congenital adrenal hyperplasia due to 21
  • hydroxylase deficiency
  • fertility
  • pregnancy outcomes
  • pregnancy related
  • hormonal substitution
  • parental project
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women with HCS due to 21-hydroxylase deficiency, confirmed genetically, and monitored in one of the participating Endocrinology departments affiliated with the CRMR of the FIRENDO network

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 or over
  • Patients with HCS due to 21-hydroxylase deficiency, confirmed genetically
  • Patients who have been informed and do not object to participating in the research

Exclusion criteria

Exclusion Criteria:

  • Patients who do not speak French
  • Patients who are not affiliated to a social security scheme or who are not entitled to it
  • Patients under legal protection, or under guardianship or trusteeship.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Interventions

  • Otherphone questionnaire

    the investigator calls the patient and asks her questions about her parental project and her pregnancies

06

What researchers measure

Primary outcomes

  1. to describe how pregnancies are achieved: spontaneous or induced, if induced by which ART technique.

    Information on how the pregnancy was achieved will be collected from the medical file and will be supplemented on the day of inclusion by a telephone questionnaire to the patient, if the data in the file do not provide answers to the study's questions.

    Time frame: Day 1

Secondary outcomes

  1. Describe the existence of a parental project among the women in the cohort

    The description of the parental project will be based on the patients' declaration of the presence or absence of a desire to have children, and if not, what the reasons were

    Time frame: Day 1

  2. Describe obstetric complications

    The description of obstetrical complications (GEU, miscarriages, in utero fetal death, IUGR, gestational diabetes, hypertension, pre-eclampsia, HELLP syndrome, cholestasis gravidarum, term of delivery, spontaneous or induced labor, birth weight, breastfeeding if desired) will be based on data from pregnancy and childbirth follow-up reports.

    Time frame: Day 1

  3. Describe the hormonal substitution adjustments.

    The description of hormone replacement adjustments will be based on the prescription of Hydrocortisone and Fludrocortisone.

    Time frame: Day 1

07

Study locations

7 of 7 sites recruiting
  • Hôpital Haut-Leveque-Service d'Endocrinologie
    Bordeaux, 33000, France
    Recruiting
  • Hospices Civiles de Lyon - Hôpital Femme Mère Enfant, Service Endocrinologie
    Bron, France
    Recruiting
  • CHIC- Service d'Endocrinologie
    Créteil, 94000, France
    Recruiting
  • AP-HP Hôpital Bicêtre - Service gynécologie Médicale
    Le Kremlin-Bicêtre, 94270, France
    Recruiting
    • Lise DURANTEAU, Dr · Contactlise.duranteau@aphp.fr · 0672156341
    • Lise Duranteau, Dr · Principal investigator
  • AP-HP Hôpital Bicêtre, Service Endocrinologie
    Le Kremlin-Bicêtre, France
    Recruiting
  • Service d'endocrinologie, Hôpital Pitié Salpêtrière
    Paris, France
    Recruiting
  • Service d'endocrinologie, Hôpital Saint Antoine
    Paris, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.

Supporting information: Study protocol, Informed consent form

Time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor

Access criteria: Researchers who provide a methodologically sound proposal.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2025
First posted
Mar 28, 2025
StartActual
Mar 13, 2026
Primary completionEst.
Mar 13, 2027
CompletionEst.
Mar 13, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 16, 2026→Mar 13, 2026
Nov 18, 2026
Primary completion
Mar 16, 2027→Mar 13, 2027
Nov 18, 2026
Study completion
Mar 16, 2027→Mar 13, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Mar 16, 2026→Mar 13, 2026
    Primary completion Mar 16, 2027→Mar 13, 2027
    Study completion Mar 16, 2027→Mar 13, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06900153
Responsible party
Sponsor
First posted
Mar 28, 2025
Start date
Mar 13, 2026
Primary completion
Mar 13, 2027 (estimated)
Completion
Mar 13, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Anne BACHELOT
Contact
anne.bachelot@aphp.fr
01 42 16 02 46

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion